Related Experiment Videos
Bone marrow transplantation for myelodysplastic syndromes
R Bélanger1, M Gyger, C Perreault
1Department of Haematology, Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada.
British Journal of Haematology
|May 1, 1988
Summary
Bone marrow transplantation (BMT) offers prolonged disease-free survival for myelodysplastic syndromes (MDS) patients under 50. Consider BMT when a compatible donor is available for MDS treatment.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Treatment options for MDS can be limited, especially for younger patients.
Purpose of the Study:
- To evaluate the efficacy and outcomes of bone marrow transplantation (BMT) in patients with myelodysplastic syndromes (MDS).
Main Methods:
- Eight patients with MDS (ages 3-45) underwent BMT.
- Conditioning regimens included cyclophosphamide/total body irradiation or busulphan/cyclophosphamide.
- Engraftment, survival, and functional status (Karnofsky score) were assessed.
Main Results:
- Engraftment occurred in seven of eight patients.
- Two treatment-related deaths occurred (veno-occlusive disease, pulmonary fibrosis).
- One patient died from disease recurrence; five patients achieved long-term remission (9-35 months), with four having Karnofsky scores >= 90%.
Conclusions:
- BMT can achieve prolonged disease-free survival in MDS patients under 50.
- Marrow transplantation is a viable treatment option for MDS if a compatible donor is available.